133 related articles for article (PubMed ID: 8971169)
1. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells.
Siders WM; Halloran PJ; Fenton RG
Cancer Res; 1996 Dec; 56(24):5638-46. PubMed ID: 8971169
[TBL] [Abstract][Full Text] [Related]
2. Melanoma-specific cytotoxicity induced by a tyrosinase promoter-enhancer/herpes simplex virus thymidine kinase adenovirus.
Siders WM; Halloran PJ; Fenton RG
Cancer Gene Ther; 1998; 5(5):281-91. PubMed ID: 9824047
[TBL] [Abstract][Full Text] [Related]
3. Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers.
Lillehammer T; Tveito S; Engesaeter BO; Fodstad O; Maelandsmo GM; Engebraaten O
Cancer Gene Ther; 2005 Nov; 12(11):864-72. PubMed ID: 15891771
[TBL] [Abstract][Full Text] [Related]
4. A transcriptional feedback loop for tissue-specific expression of highly cytotoxic genes which incorporates an immunostimulatory component.
Emiliusen L; Gough M; Bateman A; Ahmed A; Voellmy R; Chester J; Diaz RM; Harrington K; Vile R
Gene Ther; 2001 Jul; 8(13):987-98. PubMed ID: 11438833
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo targeting of gene expression to melanoma cells.
Vile RG; Hart IR
Cancer Res; 1993 Mar; 53(5):962-7. PubMed ID: 8439971
[TBL] [Abstract][Full Text] [Related]
6. MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma.
Schoensiegel F; Paschen A; Sieger S; Eskerski H; Mier W; Rothfels H; Kleinschmidt J; Schadendorf D; Haberkorn U
Cancer Gene Ther; 2004 Jun; 11(6):408-18. PubMed ID: 15118759
[TBL] [Abstract][Full Text] [Related]
7. An oncolytic adenoviral vector carrying the tyrosinase promoter for glioma gene therapy.
Ulasov IV; Rivera AA; Nettelbeck DM; Rivera LB; Mathis JM; Sonabend AM; Tyler M; Wang M; Douglas JT; Lesniak MS
Int J Oncol; 2007 Nov; 31(5):1177-85. PubMed ID: 17912445
[TBL] [Abstract][Full Text] [Related]
8. Characterization of gene regulatory elements for selective gene expression in human melanoma cells.
Artuc M; Nürnberg W; Czarnetzki BM; Schadendorf D
Biochem Biophys Res Commun; 1995 Aug; 213(2):699-705. PubMed ID: 7646526
[TBL] [Abstract][Full Text] [Related]
9. A novel attenuated replication-competent adenovirus for melanoma therapy.
Peter I; Graf C; Dummer R; Schaffner W; Greber UF; Hemmi S
Gene Ther; 2003 Apr; 10(7):530-9. PubMed ID: 12646858
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
Latham JP; Searle PF; Mautner V; James ND
Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585
[TBL] [Abstract][Full Text] [Related]
11. Short and highly efficient synthetic promoters for melanoma-specific gene expression.
Martinelli R; De Simone V
FEBS Lett; 2005 Jan; 579(1):153-6. PubMed ID: 15620705
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes.
Vile R; Miller N; Chernajovsky Y; Hart I
Gene Ther; 1994 Sep; 1(5):307-16. PubMed ID: 7584096
[TBL] [Abstract][Full Text] [Related]
13. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter.
Nettelbeck DM; Rivera AA; Balagué C; Alemany R; Curiel DT
Cancer Res; 2002 Aug; 62(16):4663-70. PubMed ID: 12183423
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional targeting of tumors with a novel tumor-specific survivin promoter.
Zhu ZB; Makhija SK; Lu B; Wang M; Kaliberova L; Liu B; Rivera AA; Nettelbeck DM; Mahasreshti PJ; Leath CA; Barker S; Yamaoto M; Li F; Alvarez RD; Curiel DT
Cancer Gene Ther; 2004 Apr; 11(4):256-62. PubMed ID: 15017380
[TBL] [Abstract][Full Text] [Related]
15. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy.
Yu DC; Sakamoto GT; Henderson DR
Cancer Res; 1999 Apr; 59(7):1498-504. PubMed ID: 10197620
[TBL] [Abstract][Full Text] [Related]
16. Triggering of antitumor activity through melanoma-specific transduction of a constitutively active tumor necrosis factor (TNF) R1 chimeric receptor in the absence of TNF-alpha.
Bazzoni F; Regalia E
Cancer Res; 2001 Feb; 61(3):1050-7. PubMed ID: 11221832
[TBL] [Abstract][Full Text] [Related]
17. The human SCGB2A2 (mammaglobin-1) promoter/enhancer in a helper-dependent adenovirus vector directs high levels of transgene expression in mammary carcinoma cells but not in normal nonmammary cells.
Shi CX; Long MA; Liu L; Graham FL; Gauldie J; Hitt MM
Mol Ther; 2004 Oct; 10(4):758-67. PubMed ID: 15451460
[TBL] [Abstract][Full Text] [Related]
18. Heat-directed gene targeting of adenoviral vectors to tumor cells.
Brade AM; Ngo D; Szmitko P; Li PX; Liu FF; Klamut HJ
Cancer Gene Ther; 2000 Dec; 7(12):1566-74. PubMed ID: 11228535
[TBL] [Abstract][Full Text] [Related]
19. Cloning and analysis of human UroplakinII promoter and its application for gene therapy in bladder cancer.
Zhu HJ; Zhang ZQ; Zeng XF; Wei SS; Zhang ZW; Guo YL
Cancer Gene Ther; 2004 Apr; 11(4):263-72. PubMed ID: 14963492
[TBL] [Abstract][Full Text] [Related]
20. High-level, beta-catenin/TCF-dependent transgene expression in secondary colorectal cancer tissue.
Lipinski KS; Djeha AH; Ismail T; Mountain A; Young LS; Wrighton CJ
Mol Ther; 2001 Oct; 4(4):365-71. PubMed ID: 11592840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
